top of page

Roivant's Matt Gline on the success of Telavant, Immunovant's FcRn program, and his expectations for the company's cash usage

Matt Gline reflects on learnings from the Telavant success, why he thinks Immunovant's FcRn might be best in class, and how Roivant's asset hunting has been going lately.

Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page